1. Updates in Progressive MS

2. Therapeutic Milieu for Progressive MS

3. Ocrelizumab

4. Anti-inflammatory Properties of DMTs for PPMS

5. Treating Active SPMS Siponimod

6. Labeling for Novel Agents in Progressive MS

7. A Novel Treatment in Active SPMS Cladribine

8. FDA Is Using Phenotypic Classification for Progressive MS

9. Improved Efficacy in Progressive MS With Next-Generation S1P Inhibitor

10. PPMS vs SSPS What Is the Difference?

11. Can Anti-Inflammatory Intervention Prevent SP Disease?

12. Progressive MS is a Multifactorial Disease

13. Silent Progression

14. Brain Atrophy in PPMS vs SPMS Treated With Ibudilast

15. Biomarkers for SPMS CNS Inflammation

16. Biomarkers for SPMS CNS Inflammation: Results

17. Biomarkers for SPMS Cervical Cord Atrophy

18. Biomarkers for SPMS Cervical Cord Atrophy (cont)

19. Biomarkers for SPMS Atrophied T2-LV

20. Biomarkers for SPMS NfL

21. Concluding Remarks

22. Abbreviations

23. Abbreviations (cont)

24. Abbreviations (cont)